Related Experiment Video
Updated: Aug 15, 2025

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Revisiting live attenuated influenza vaccine efficacy among children in developing countries
Sumedha Bagga1, Anand Krishnan2, Lalit Dar1
1Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Insights
Live attenuated influenza vaccines (LAIVs) show promise for children in developing nations. However, their efficacy varies, necessitating further research into factors like viral strain selection for optimal pediatric influenza protection.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Global health
Background:
- Seasonal influenza causes significant global pediatric mortality and morbidity.
- Live attenuated influenza vaccines (LAIVs) offer advantages like intranasal administration and higher manufacturing yields compared to inactivated influenza vaccines (IIVs).
- LAIVs are particularly attractive for children in developing countries due to disease burden and logistical benefits.
Purpose of the Study:
- To summarize recent pediatric studies on LAIV efficacy in developing countries.
- To analyze factors contributing to the varied efficacy of LAIVs in diverse settings.
- To inform strategies for improving LAIV utility in resource-poor regions.
Main Methods:
- Review of recent randomized controlled trials (RCTs) evaluating LAIV efficacy in pediatric populations.
- Analysis of vaccine efficacy data from studies conducted in Bangladesh, Senegal, and India.
- Examination of historical data and recommendations from the CDC Advisory Committee on Immunization Practices (ACIP).
Main Results:
- Conflicting LAIV efficacy results were reported in trials in Bangladesh (41%) and Senegal (0.0%).
- Previous Ann Arbor-based LAIV showed higher efficacy than IIV before 2013, but faced challenges with influenza A(H1N1)pdm09 strains.
- A recent Indian RCT indicated lower LAIV efficacy compared to IIV in Year 1, with comparable efficacy in Year 2.
Conclusions:
- The efficacy of LAIVs in developing countries is variable and requires deeper mechanistic understanding.
- Assessing replicative fitness alongside antigenicity is crucial for selecting annual influenza A(H1N1)pdm09 components for Russian-backbone LAIVs.
- Optimizing LAIVs based on these factors could enhance their widespread use in resource-limited settings.
Abstract:
Seasonal influenza epidemics cause significant pediatric mortality and morbidity worldwide. Live attenuated influenza vaccines (LAIVs) can be administered intranasally, induce a broad and robust immune response, demonstrate higher yields during manufacturing as compared to inactivated influenza vaccines (IIVs), and thereby represent an attractive possibility for young children in developing countries. We summarize recent pediatric studies evaluating LAIV efficacy in developing countries where a large proportion of the influenza-virus-associated respiratory disease burden occurs. Recently, two randomized controlled trials (RCTs) assessing Russian-backbone trivalent LAIV in children reported contradictory results; vaccine efficacy varied between Bangladesh (41 %) and Senegal (0.0 %) against all influenza viral strains. Prior to 2013, Ann Arbor-based LAIV demonstrated superior efficacy as compared to IIV. However, due to low effectiveness of the Ann Arbor-based LAIV against influenza A(H1N1)pdm09-like viruses, the CDC Advisory Committee on Immunization Practices (ACIP) recommended against the use of LAIV during the 2016-17 and 2017-18 influenza seasons. Reduced replicative fitness of the A(H1N1)pdm09 LAIV strains is thought to have led to the low effectiveness of the Ann-Arbor-based LAIV. Once the A(H1N1)pdm09 component was updated, the ACIP reintroduced the Ann-Arbor-based LAIV as a vaccine choice for the 2018-19 influenza season. In 2021, results from a 2-year RCT evaluating the Russian-backbone trivalent LAIV in rural north India reported that LAIV demonstrated significantly lower efficacy compared to IIV, but in Year 2, the vaccine efficacy for LAIV and IIV was comparable. A profounder understanding of the mechanisms underlying varied efficacy of LAIV in developing countries is warranted. Assessing replicative fitness, in addition to antigenicity, when selecting annual A(H1N1)pdm09 components in the Russian-backbone trivalent LAIVs is essential and may ultimately, enable widespread utility in resource-poor settings.
More Related Videos
12:09Measuring Influenza Neutralizing Antibody Responses to AH3N2 Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
Published on: November 22, 2017
06:34An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017